Japan Dry Eye Disease Diagnostic Market Market Report 2023 to 2030

Japan Dry Eye Disease Diagnostic Market Analysis

$ 3999

Japan Dry Eye Disease Diagnostics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Dry Eye disease diagnostics is expanding as a result of rising prevalence of the disease. This demand is fueling the development of better diagnostic tools and methods for the early detection and accurate diagnosis of Dry Eye disease. Some of the key players in the global Dry Eye Disease Diagnostics Market include Novartis AG, AbbVie, Inc., Sun Pharmaceutical Industries Ltd., Santen Pharmaceutical Co., Ltd., AFT Pharmaceuticals, Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., OASIS Medical, Oyster Point Pharma, Inc., Bausch & Lomb, Allergan Plc, and Sentiss Pharma Pvt. Ltd.

ID: IN10JPHS046 CATEGORY: Healthcare Services GEOGRAPHY: Japan AUTHOR: Aneri Parekh

Buy Now

Japan Dry Eye Disease Diagnostic Market Executive Summary

Japan Dry Eye Disease Diagnostic Market is valued at around $3.95 Bn in 2022 and is projected to reach $5.79 Bn by 2030, exhibiting a CAGR of 4.9% during the forecast period 2023-2030.

The Dry Eye Disease Diagnostics Market refers to the market for tools and methods used to diagnose Dry Eye disease, which occurs when tears aren’t able to provide adequate moisture. The market includes software and platforms for analysing and interpreting the findings of diagnostic tests and imaging methods used to detect the disease.

The increased prevalence of Dry Eye disease, which is expected to impact the young as well as geriatric population, has contributed to the growth of the global market for Dry Eye disease diagnostics in recent years. Advances in diagnostic technologies and imaging methodologies are also driving the market.

Pharmaceutical and biotechnology firms like Novartis AG, AbbVie, Inc., Sun Pharmaceutical Industries Ltd., Santen Pharmaceutical Co., Ltd., AFT Pharmaceuticals, Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., OASIS Medical, Oyster Point Pharma, Inc., Bausch & Lomb, Allergan Plc, and Sentiss Pharma Pvt. Ltd., are some of the major players in the Dry Eye Disease Diagnostics Market.

Dry Eye disease is diagnosed using a variety of diagnostic procedures and tests, including reduced Schirmer test result, reduced tear film break-up time (TBUT), and positive ocular surface staining. It uses an osmolarity testing device, meibography dry eye diagnosis system, and an interferometry dry eye diagnosis system to diagnose the disease.

The ageing global population, use of screens, and rising knowledge of Dry Eye disease are projected to fuel the market for diagnostics for the condition. The market may yet have difficulties with regard to strict drug approval mechanisms of testing bodies leading to the delayed launch of new drugs and funding for diagnostic procedures and therapies, as well as the high price of various diagnostic methods and instruments.

Market Dynamics

Drivers of Japan Dry Eye Disease Diagnostics Market:

Rise in Incidence and Prevalence of Dry Eye Disease: Due to the constant use of screens, improper diet, use of contact lenses, and an increasing number of LASIK surgery, the prevalence of the disease is increasing leading to growth in Dry Eye Disease Diagnostics Market.

Growing Geriatric Population: The ability of lachrymal glands to produce tears decreases with age leading to dry eye disease and hence boosting the growth of the Dry Eye Disease Diagnostics Market.

Growing Awareness among People: The growing awareness about dry eye disease and its symptoms is leading people to undergo its treatment, increasing the sales of the Dry Eye Disease Diagnostics Market.

High Disposable Income: With an increase in disposable income and standard of care, more people are opting for the treatment of dry eye disease leading to the expansion of the Dry Eye Disease Diagnostics Market.

Increase in Investment for Healthcare Structure: The expenditure on healthcare is rising leading to the growth of the Dry Eye Disease Diagnostics Market.

Restraints of Japan Dry Eye Disease Diagnostics Market:

High Cost of Treatment: The high costs of treatment can obstruct the growth of the Dry Eye Disease Diagnostics Market.

Strict Drug Approval Mechanism: The launch of new drugs can be delayed due to regulatory aspects of drug approval mechanisms of testing bodies.

Notable Deals in Dry Eye Disease Diagnostics Market:

In 2022, Alderya Therapeutics, Inc. completed the phase 3 clinical trial of 0.25% reproxalap ophthalmic solution for treating allergic conjunctivitis.

In 2022, NovaBay Pharmaceuticals launched Avenova lubricating eye drops to treat dry eye symptoms.

In 2022, Novartis, a pharmaceutical company, acquired AcuStreaM technology from Kedalion Therapeutics with the intention of expanding Novartis’ product line and addressing patients’ unmet needs in front-of-eye disorders.

In 2022, Theravision and Ketotifen, an etafilcon, a drug-eluting contact lens that also contains Ketotifen, was approved by FDA for sale by Johnson & Johnson Vision.

In 2022, Sun Pharma announced the launch of its treatment product, Cequa. This technique improves the bioavailability and physiochemical stability of cyclosporine and enhances its penetration into the eye tissues.

This technique improves the bioavailability and physicochemical stability of cyclosporine and enhances its penetration into the eyes tissue.

Key players

Santen Pharmaceutical Co., Ltd. Alcon Japan Ltd. Takeda Pharmaceutical Company Limited Johnson & Johnson Vision Care Japan Otsuka Pharmaceutical Co., Ltd. Bausch Health Japan, Ltd. Topcon Corporation Hoya Corporation Carl Zeiss Meditec Japan K.K. Nidek Co., Ltd.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Japan Dry Eye Disease Diagnostics Market

By Product:

Artificial Tears
Anti-inflammatory Drugs
Punctal Plugs
Secretagogues
Other Products

By Distribution:

Hospital Pharmacy
Independent Pharmacy
Drug Store
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.